| Bioactivity | Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer[1]. |
| Invitro | Naptumomab estafenatox (0.001-10000 pM；4 小时) 对人葡萄球菌肠毒素 A (SEA) 介导的 T 细胞对 Caki-2 和 Raji 细胞的 EC50 分别为 20 和 30000 pM[1]。Naptumomab estafenatox (0.001-10000 pM；4 小时) 对 SEA/E-120 介导的 T 细胞对 Caki-2 和 Raji 细胞的 EC50 分别为 0.1 和 100000 pM[1]。Naptumomab estafenatox (1 pM-1 μM；4 天) 剂量依赖性地诱导人淋巴细胞增殖[1]。 Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Naptumomab estafenatox (0.016 mg；静脉注射，每日 1 次，共 8 天) 对有 Calu-1 肿瘤的免疫缺陷小鼠具有抗肿瘤作用[1]。 Animal Model: |
| Name | Naptumomab estafenatox |
| CAS | 676258-98-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Forsberg G, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010 Jun;33(5):492-9. [2]. Elkord E, et al. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget. 2015 Feb 28;6(6):4428-39. |